The HER family as therapeutic targets in colorectal cancer

This publication has 172 references indexed in Scilit:

• Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies
  Cell Death & Disease, 2013
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  The Lancet Oncology, 2010
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
  The Lancet, 2010
• ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
  Proceedings of the National Academy of Sciences, 2010
• Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
  British Journal of Cancer, 2010
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
  British Journal of Cancer, 2009
• Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
  Cancer Cell, 2009
• K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
  New England Journal of Medicine, 2008
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
  Annals of Oncology, 2008
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
  Nature, 2003